A. Lisyanskaya

发表

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.

A. Oza, I. Bondarenko, N. Colombo, 2022, The Lancet. Oncology.

A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.

M. Buyse, I. Vergote, H. Bjermo, 2019, Gynecologic oncology.

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

J. Ledermann, J. Sehouli, U. de Giorgi, 2021, ESMO open.

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.

A. Oza, M. Friedlander, Byoung-Gie Kim, 2021, The Lancet. Oncology.

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.

D. Provencher, J. Ledermann, M. Birrer, 2018 .

O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma

Shin-ichiro Takahashi, A. Oaknin, D. Lorusso, 2021, Oral Abstracts.

EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.

I. Vergote, I. Lowy, C. Ivanescu, 2022, European journal of cancer.

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Gabe S. Sonke, Anne Floquet, Kathleen Moore, 2018, The New England journal of medicine.

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.

A. Oza, E. Parkhomenko, M. Friedlander, 2021, The Lancet. Oncology.

Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.

A. Oza, M. Friedlander, Byoung-Gie Kim, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.

I. Vergote, G. Scambia, D. Dizon, 2015, Gynecologic oncology.

Survival with Cemiplimab in Recurrent Cervical Cancer.

B. Monk, Chih-Long Chang, S. Lheureux, 2022, The New England journal of medicine.

Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1

A. Oza, M. Friedlander, Byoung-Gie Kim, 2021, Gynecologic Oncology.

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

A. Oza, J. Ledermann, T. Park-Simon, 2020 .

519MO Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis

B. Monk, Shin-ichiro Takahashi, V. Samouëlian, 2022, Annals of Oncology.

A randomized phase II clinical trial of the SRC inhibitor saracatinib (AZD0530) and carboplatin plus paclitaxel (C plus P) versus C plus P in patients (pts) wiht advanced platinum-sensitive epithelial ovarian cancer (eoc)

Gunnar B. Kristensen, S. Rodenhuis, C. Poole, 2010 .

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

Jae-Weon Kim, A. Oza, M. Friedlander, 2021, Gynecologic oncology.

518O Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation

A. Oza, D. Cibula, K. Mclachlan, 2022, Annals of Oncology.

811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1

A. Oza, M. Friedlander, C. Aghajanian, 2020 .

Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.

A. Oza, M. Friedlander, Byoung-Gie Kim, 2019, Journal of Clinical Oncology.

Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study.

D. Provencher, J. Ledermann, M. Birrer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma

B. Monk, Shin-ichiro Takahashi, V. Samouëlian, 2021, Annals of Oncology.

Non-interventional study OVATAR final report: Diagnostic and treatment approaches in Russian ovarian cancer population—BRCAm group analysis.

S. Tjulandin, V. Gorbunova, A. Lisyanskaya, 2019, Journal of Clinical Oncology.

Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.

D. Provencher, J. Ledermann, M. Birrer, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.